<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-100616" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cefotaxime</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-100616.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cefotaxime is a medication used to manage and treat cervicitis/urethritis and pneumonia. Cefotaxime is a beta-lactam antibiotic classified as a third-generation cephalosporin. Its broad-spectrum antibacterial activity is useful in treating the susceptible strains of bacteria affecting the lower respiratory tract, genito-urinary tract, central nervous system, intra-abdominal infections, bone and joint infections, skin infections, gynecologic infections, and septicemia. This activity outlines the indications, mechanism of action, and contraindications for cefotaxime is a valuable agent in treating and managing bacterial infections. This activity will highlight the mechanism of action, adverse event profile, resistance, and other key factors pertinent to healthcare team members in the care of patients with pneumonia and urethritis/cervicitis and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of cefotaxime resistance.</p></list-item><list-item><p>Identify the most common adverse events associated with cefotaxime therapy.</p></list-item><list-item><p>Outline the mechanism of action of cefotaxime.</p></list-item><list-item><p>Review some interprofessional team strategies for improving care coordination and communication to advance cefotaxime and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100616">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-100616.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cefotaxime is a&#x000a0;beta-lactam antibiotic&#x000a0;classified as a third-generation cephalosporin, which was first synthesized in 1976 and is FDA approved to treat gram-positive, gram-negative, and anaerobic bacteria.<xref ref-type="bibr" rid="article-100616.r1">[1]</xref>&#x000a0;Its broad-spectrum antibacterial activity is useful in treating the susceptible strains of bacteria affecting the lower respiratory tract, genito-urinary&#x000a0;tract, central nervous system, intra-abdominal infections, bone and joint infections,&#x000a0;skin infections, gynecologic infections, and septicemia.<xref ref-type="bibr" rid="article-100616.r2">[2]</xref> Cefotaxime may also be used prophylactically prior to surgery to prevent surgical infections.</p>
        <p>Among the susceptible strains, <italic toggle="yes">Enterobacteriaceae</italic> is particularly sensitive to cefotaxime and may treat multi-drug resistant strains of <italic toggle="yes">Enterobacteriaceae</italic>.<xref ref-type="bibr" rid="article-100616.r3">[3]</xref>&#x000a0;Although it has a broad spectrum of bactericidal activity, it is not as effective against pseudomonas aeruginosa infections compared to other third-generation antibiotics and is not recommended as monotherapy.<xref ref-type="bibr" rid="article-100616.r3">[3]</xref>&#x000a0;Intramuscular treatment with cefotaxime for sexually transmitted infections with <italic toggle="yes">Neisseria gonorrhoeae</italic> has shown a positive outcome in both men and women.&#x000a0;Cefotaxime has beneficial therapeutic activity treating pneumonia affecting the lower respiratory tract primarily caused by Gram-negative bacilli, and the bactericidal agent has shown significant efficacy in treating complicated infections affecting the urinary tract.<xref ref-type="bibr" rid="article-100616.r4">[4]</xref>&#x000a0;</p>
        <p>Compared with the other cephalosporins, a favorable characteristic of cefotaxime is that it does not cause a notable occurrence of coagulopathies and pseudocholelithiasis.<xref ref-type="bibr" rid="article-100616.r4">[4]</xref>&#x000a0;Trials comparing cefotaxime with the third-generation cephalosporin ceftriaxone have exhibited similar clinical efficiency.<xref ref-type="bibr" rid="article-100616.r4">[4]</xref>&#x000a0;Clinical trials have also shown 75% to 100% resolution in hospitalized patients with moderate to severe infections.<xref ref-type="bibr" rid="article-100616.r5">[5]</xref><xref ref-type="bibr" rid="article-100616.r4">[4]</xref>&#x000a0;Cefotaxime may also be interchangeable with ceftriaxone as off-label use for the treatment of endocarditis by&#x000a0;<italic toggle="yes">Haemophilus parainfluenzae</italic>, <italic toggle="yes">H. aphrophilus</italic>, <italic toggle="yes">Actinobacillus actinomycetemcomitans</italic>, <italic toggle="yes">Cardiobacterium hominis</italic>, <italic toggle="yes">Eikenella corrodens</italic>, and&#x000a0;<italic toggle="yes">Kingella kingae&#x000a0;</italic>(HACEK) organisms.<xref ref-type="bibr" rid="article-100616.r6">[6]</xref>&#x000a0;Cefotaxime can readily cross the blood-brain barrier when administered intravenously and may treat gram-negative infections resistant to previous generations of cephalosporins.<xref ref-type="bibr" rid="article-100616.r7">[7]</xref></p>
        <p>
<bold>Susceptible Organisms</bold>
</p>
        <p>Gram-positive bacteria</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Enterococcus spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Staphylococcus aureus</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Staphylococcus epidermidis</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Streptococcus pneumoniae</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Streptococcus pyogenes</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Streptococcus viridans spp</italic>
</p>
          </list-item>
        </list>
        <p>Anaerobic bacteria</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Bacteroides spp.</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Clostridium spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Fusobacterium spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Peptococcus spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Peptostreptococcus spp</italic>
</p>
          </list-item>
        </list>
        <p>Gram-negative bacteria</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Acinetobacter spp.</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Citrobacter spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Enterobacter spp</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Escherichia coli</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Haemophilus influenzae</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Haemophilus parainfluenzae</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Klebsiella spp.</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Morganella morganii</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Neisseria gonorrhoeae&#x000a0;</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Neisseria meningitidis</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Proteus mirabilis</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Proteus vulgaris</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Providencia rettgeri</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Providencia stuartii</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Serratia marcescens</italic>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-100616.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cefotaxime is a bactericidal agent that exerts its mechanism of action by binding penicillin-binding proteins (PBPs) via beta-lactam rings and inhibiting the definitive activity of transpeptidation in peptidoglycan cell wall synthesis of susceptible bacterial organisms.<xref ref-type="bibr" rid="article-100616.r8">[8]</xref><xref ref-type="bibr" rid="article-100616.r9">[9]</xref>&#x000a0;Its action demonstrates a great affinity for PBP Ib and PBP III cell wall proteins.</p>
        <p>The inability to form a bacterial cell wall further causes the autolysis of the bacteria.<xref ref-type="bibr" rid="article-100616.r7">[7]</xref>&#x000a0;Similarly to other third-generation cephalosporins, its broad spectrum action makes it efficacious against gram-positive and gram-negative bacteria.</p>
        <p>
<bold>Resistance</bold>
</p>
        <p>Beta-lactamases can cause hydrolysis to cefotaxime, further hindering its bactericidal effects. Although susceptive, cefotaxime is quite durable against the activity of most &#x003b2;-lactamases.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Once administered, cefotaxime undergoes metabolism&#x000a0;within&#x000a0;the liver, and the majority of it is excreted renally. In the liver, cefotaxime&#x000a0;converts to desacetylcefotaxime, which is further converted to desacetylcefotaxime lactone and then to M metabolites.<xref ref-type="bibr" rid="article-100616.r10">[10]</xref>&#x000a0;More than 80% is recovered in the urine, with one-third being in the form of desacetylcefotaxime (des-CTX).&#x000a0;Although desacetylcefotaxime (des-CTX) is the major metabolite of cefotaxime, its activity is eight-fold weaker than cefotaxime.<xref ref-type="bibr" rid="article-100616.r11">[11]</xref></p>
      </sec>
      <sec id="article-100616.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cefotaxime is available and distributed in powder form and as a premixed solution for intramuscular and intervenous administration. The powder form is available in 500 mg, 1 g, 2 g, and 10 g vials. The premixed solution is available as 1g and 2g&#x000a0;for&#x000a0;injection.</p>
        <p>
<bold>Gonococcal Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Urethritis (Males): 0.5 g intramuscular injection (can be administered as a single dose)</p>
          </list-item>
          <list-item>
            <p>Cervicitis (Females): 0.5 g&#x000a0;intramuscular injection&#x000a0;(can be administered as a single dose)</p>
          </list-item>
          <list-item>
            <p>Rectal infection (Males): 1 g&#x000a0;intramuscular injection&#x000a0;(can be administered as a single dose)</p>
          </list-item>
          <list-item>
            <p>Rectal infection( Females): 0.5 g&#x000a0;intramuscular injection&#x000a0;(can be administered as a single dose)</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Cefotaxime has no coverage for Chlamydia trachomatis, and treatment should be added if this organism is suspected.</italic>
</p>
        <p>
<bold>Septicemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 g I.V. every 6&#x000a0;to 8 hours. (Daily dose of 6&#x000a0;to 8 grams)</p>
          </list-item>
        </list>
        <p>
<bold>Spontaneous Bacterial Peritonitis (SBP)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cefotaxime is the drug of choice in patients with SBP due to&#x000a0;its ability to achieve excellent levels in the&#x000a0;blood and ascitic fluid. The typical dose in SBP would be 2 g intravenous every 8 hours.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Uncomplicated Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 g intramuscular or IV every 12 hours. (Daily dose of 2 grams)</p>
          </list-item>
        </list>
        <p>
<bold>Moderate to Severe Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1&#x000a0;to 2 g intramuscular or IV every 8 hours. (Daily dose of 3&#x000a0;to 6 grams)</p>
          </list-item>
        </list>
        <p>
<bold>Life-threatening Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>2 g intramuscular or IV every 4 hours. (Daily dose of&#x000a0;12 grams)</p>
          </list-item>
        </list>
        <p>
<bold>Cesarean Section</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First dose: 1 g IV (Umbilical cord should be clamped)</p>
          </list-item>
          <list-item>
            <p>Second dose:&#x000a0;1 g intramuscular or IV (six hours&#x000a0;after the first dose)</p>
          </list-item>
          <list-item>
            <p>Third dose:&#x000a0;1 g intramuscular or IV&#x000a0;(twelve hours&#x000a0;after the first dose)</p>
          </list-item>
        </list>
        <p>
<bold>Surgery Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 g intramuscular or IV 30 minutes before surgery.</p>
          </list-item>
        </list>
        <p>
<bold>Neonates (age 0&#x000a0;to 4 weeks)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>(Age 0&#x000a0;to 1 week) 50 mg/kg per dose&#x000a0;IV every 12 hours</p>
          </list-item>
          <list-item>
            <p>(Age 1&#x000a0;to 4 weeks) 50 mg/kg per dose&#x000a0;IV every 8 hours</p>
          </list-item>
        </list>
        <p>
<bold>Infants and Children (age 1 month to 12 years old)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>50 to 180 mg/kg intramuscular or IV every 6 to 8 hours (for individuals with body weight &#x0003c;50kg)</p>
          </list-item>
          <list-item>
            <p>1&#x000a0;to 2 grams intramuscular or IV every 8 hours.&#x000a0;(for individuals with body weight &#x0003e;50kg)</p>
          </list-item>
        </list>
        <p>Individuals with a body weight&#x0003e;50 kg should follow adult dosing. The daily dosage should not exceed 12 grams for infants and children.</p>
      </sec>
      <sec id="article-100616.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <list list-type="bullet">
          <list-item>
            <p>Local reaction: pain, swelling</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity: rash, pruritis, anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal effects: nausea, vomiting, diarrhea</p>
          </list-item>
          <list-item>
            <p>Pseudomembranous Colitis</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Elevation in liver enzymes</p>
          </list-item>
          <list-item>
            <p>Elevation in BUN and creatinine</p>
          </list-item>
          <list-item>
            <p>Hematologic: Neutropenia, leukopenia, agranulocytosis</p>
          </list-item>
        </list>
        <p>Local reactions such as pain, swelling, and rash are the most common adverse effects&#x000a0;following cefotaxime administration. Like other cephalosporins, cefotaxime&#x000a0;does not cause disulfiram-like reactions. Cefotaxime used concurrently with nephrotoxic agents may&#x000a0;promote&#x000a0;nephrotoxic effects on the kidney, and such use requires caution. Patients with hypersensitivity to the cephalosporin or penicillin group may result in an anaphylactic reaction and are manageable with epinephrine, antihistamines, vasopressors, or corticosteroids.</p>
      </sec>
      <sec id="article-100616.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity to cefotaxime is an absolute contraindication to its use. Patients with known allergies to penicillin or other cephalosporins should also avoid cefotaxime.</p>
      </sec>
      <sec id="article-100616.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Cefotaxime&#x000a0;administration and dosing require adjusting in&#x000a0;geriatric populations, patients with decreased renal function, and hepatic dysfunction.&#x000a0;Renal function&#x000a0;and liver enzymes&#x000a0;require routine monitoring.&#x000a0;The half-life of cefotaxime is generally one hour, and severe kidney dysfunction may prolong the half-life of cefotaxime and its metabolite desacetylcefotaxime.<xref ref-type="bibr" rid="article-100616.r9">[9]</xref>&#x000a0;CBC should also be monitored with cefotaxime use as there are reports of hematologic changes such as neutropenia, leukopenia, and agranulocytosis. Cefotaxime, like other cephalosporins, may also cause a false positive direct coombs test.</p>
        <p>Cefotaxime is an FDA Pregnancy Category B drug. Cefotaxime use in pregnancy has not been studied clearly and should be used cautiously. Cefotaxime is reported to cross the placenta during pregnancy. It is also present in low&#x000a0;concentrations in breast milk during lactation.&#x000a0;</p>
      </sec>
      <sec id="article-100616.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Cefotaxime is metabolized&#x000a0;by&#x000a0;the liver and excreted through the kidneys, and dysfunctions may result in decreased drug clearance&#x000a0;leading to&#x000a0;increased plasma concentrations.&#x000a0;About 50&#x000a0;to 60% of the agent is excreted unchanged, and 15 to 20%&#x000a0;is&#x000a0;excreted as a desacetyl metabolite desacetylcefotaxime.<xref ref-type="bibr" rid="article-100616.r9">[9]</xref>&#x000a0;Toxicity may result in convulsions, dyspnea, hypothermia, cyanosis, reversible encephalopathy, and death. Mortality has occurred with dosages of 6000 mg/kg/day. Treatment for cefotaxime toxicity requires supportive management.</p>
      </sec>
      <sec id="article-100616.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cefotaxime is a broad-spectrum antibiotic that is FDA-approved and indicated to treat gram-positive, gram-negative, and anaerobic organisms of susceptible strains causing pneumonia, urinary tract infections, cervicitis, endometritis, urethritis, and sepsis.&#x000a0;The care for patients suffering from infectious diseases prompts critical care from an interprofessional team of healthcare professionals, as preventable contagious disorders can lead to medication resistance, complications, and mortality. These healthcare professionals include a primary care physician, an internist, an infectious disease specialist, critical care, a gynecologist, a nurse, and a pharmacist.</p>
        <p>Primary care clinicians, internists, and specialists should educate the patients about the consequences of non-compliance with therapy for the full duration and how resistance to treatment can further cause complications and result in mortality. The primary care physician should routinely monitor renal function, liver enzymes, and CBC as cefotaxime is metabolized and cleared in the liver and kidneys, respectively, and has also been shown to cause hematologic adverse effects. Cefotaxime should be renally dosed in patients with compromised renal function, such as CKD or ESRD, and patients receiving hemodialysis.&#x000a0;</p>
        <p>Patients developing diarrhea while receiving treatment with antibiotics should be assessed for <italic toggle="yes">Clostridium difficile</italic> infection. Colonic flora is changed when receiving treatment with antibiotics, making it susceptible to Clostridium difficile infection resulting in mild to severe forms of diarrhea. Diagnostics and treatment focused on <italic toggle="yes">Clostridium difficile</italic>, electrolyte, and volume depletion should be initiated, and discontinuing management with cefotaxime should be considered.</p>
        <p>Counseling and&#x000a0;careful monitoring&#x000a0;are necessary during pregnancy, as clinical studies during its use in pregnancy are limited, and cefotaxime FDA pregnancy category B. Cefotaxime is reported to also be present in breastmilk in low amounts, and infants should be monitored accordingly.<xref ref-type="bibr" rid="article-100616.r12">[12]</xref> Physicians should be up to date with the newly FDA-approved cefotaxime indications dosing, and their effects in the event drug resistance does develop.</p>
        <p>During the treatment of gonorrhea causing urethritis or cervicitis, treatment for chlamydia should be added as cefotaxime does not have coverage for this organism. An interprofessional healthcare team approach to antimicrobial care with cefotaxime involving collaborative interventions and communication is key to building patient rapport and developing a therapeutic alliance so the patients comply with therapy adequately&#x000a0;to eradicate the bacteria&#x000a0;and prevent&#x000a0;further spread.&#x000a0;Continued communication and teamwork between healthcare professionals will improve antimicrobial stewardship, improve patient outcomes, limit microbial resistance, and lower the incidence of multidrug-resistant organisms.</p>
      </sec>
      <sec id="article-100616.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100616">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/100616/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=100616">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-100616.s11">
        <title>References</title>
        <ref id="article-100616.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dudley</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Barriere</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime: microbiology, pharmacology, and clinical use.</article-title>
            <source>Clin Pharm</source>
            <year>1982</year>
            <season>Mar-Apr</season>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-24</page-range>
            <pub-id pub-id-type="pmid">6309465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime. An update of its pharmacology and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>608</fpage>
            <page-range>608-51</page-range>
            <pub-id pub-id-type="pmid">2083516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmine</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-89</page-range>
            <pub-id pub-id-type="pmid">6303743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.</article-title>
            <source>Pharmacoeconomics</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1 Pt 1</issue>
            <fpage>91</fpage>
            <page-range>91-106</page-range>
            <pub-id pub-id-type="pmid">10175990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.</article-title>
            <source>Drugs</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>483</fpage>
            <page-range>483-510</page-range>
            <pub-id pub-id-type="pmid">9074846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ferrieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tani</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falace</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newburger</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pallasch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <collab>Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease</collab>
              <collab>Council on Cardiovascular Disease in the Young</collab>
              <collab>Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia</collab>
              <collab>American Heart Association</collab>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.</article-title>
            <source>Circulation</source>
            <year>2005</year>
            <month>Jun</month>
            <day>14</day>
            <volume>111</volume>
            <issue>23</issue>
            <fpage>e394</fpage>
            <page-range>e394-434</page-range>
            <pub-id pub-id-type="pmid">15956145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Cephalosporins</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31855361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lassman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Coombes</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of cefotaxime: a review.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>3 Suppl</issue>
            <fpage>3S</fpage>
            <page-range>3S-12S</page-range>
            <pub-id pub-id-type="pmid">6086216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeFrock</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Leff</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime.</article-title>
            <source>Pharmacotherapy</source>
            <year>1982</year>
            <season>Jul-Aug</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>174</fpage>
            <page-range>174-84</page-range>
            <pub-id pub-id-type="pmid">6302641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coombes</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of cefotaxime in animals and humans.</article-title>
            <source>Rev Infect Dis</source>
            <year>1982</year>
            <season>Sep-Oct</season>
            <volume>4 Suppl</volume>
            <fpage>S325</fpage>
            <page-range>S325-32</page-range>
            <pub-id pub-id-type="pmid">6294781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>NX</given-names>
              </name>
              <name>
                <surname>Neu</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>3 Suppl</issue>
            <fpage>21S</fpage>
            <page-range>21S-31S</page-range>
            <pub-id pub-id-type="pmid">6086215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100616.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Cefotaxime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000425</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
